Comment on "The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study"
- PMID: 35378641
- DOI: 10.1007/s11060-022-04000-z
Comment on "The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study"
Comment on
-
The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.J Neurooncol. 2022 Mar;157(1):177-185. doi: 10.1007/s11060-022-03960-6. Epub 2022 Feb 17. J Neurooncol. 2022. PMID: 35175545
References
-
- Ramos-Fresnedo A, Pullen MW, Perez-Vega C et al (2022) The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J Neurooncol. https://doi.org/10.1007/s11060-022-03960-6 - DOI - PubMed
-
- Louis DN (2022) Glioblastoma, IDH-wildtype in: WHO classification of tumors: central nervous system tumors. International Agency for Research on Cancer (IARC). https://tumourclassification.iarc.who.int/chaptercontent/45/7 . Accessed 4 March 2022.
-
- Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 136:805–810. https://doi.org/10.1007/s00401-018-1913-0 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
